Myovant, Sumitomo Beat Investor Suit Over Skadden Advice

By Katryna Perera · January 2, 2024, 10:22 PM EST

Sumitomo Pharma America Inc. and Myovant Sciences Ltd. have escaped for good a proposed class action alleging the companies' merger was undervalued because the lawyers from Skadden Arps Slate Meagher &...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

Zappia v. Myovant Sciences Ltd. et al

Case Number

Court

New York Southern

Nature of Suit

Securities/Commodities

Date Filed

September 13, 2023

Recent Articles By Katryna

September 27, 2024
Pharma Co. Amarin Beats Class Action Over Patent Issues
September 26, 2024
Healthcare REIT Defeats Investor Suit For Good
September 23, 2024
Mallinckrodt Brass Can't Avoid Investor Suit Over 2nd Ch. 11
September 23, 2024
SEC Scores $12M Judgment In Unregistered Dealer Case
September 05, 2024
Pharma Co. Verrica Fails To Shed Investor Suit Over FDA OK
August 21, 2024
Health Co. Investors Fight To Keep Suit Over Migrant Deal
August 06, 2024
Pharma Co. Founder Beats Suit Over Short-Swing Trading
August 05, 2024
Indivior Accused Of Overstating Prospects Of 3 Opioid Drugs
August 05, 2024
Centessa Beats Shareholder Suit Over Kidney Drug
July 30, 2024
Judge Wants Device Warning Answers From Mich. Justices